CAU
FOLD

Caxton Associates (UK)’s Amicus Therapeutics FOLD Stock Holding History

Caxton Associates (UK)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,396
Closed -$162K – 857
2025
Q4 		$162K Buy
+11,396
New +$112K ﹤0.01% 728
2025
Q2 		– Sell
-58,114
Closed -$474K – 764
2025
Q1 		$474K Buy
+58,114
New +$538K 0.02% 504

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Caxton Associates (UK)'s FOLD Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 11,396 shares — an estimated $162K sold.

Caxton Associates (UK) first reported a position in FOLD in Q1 2025 and held it in 2 quarters. The position peaked at $474K in Q1 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 11,396 Amicus Therapeutics shares in Q1 2026, an estimated $162K.
  • Caxton Associates (UK) first reported a position in Amicus Therapeutics in Q1 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Amicus Therapeutics position peaked at $474K in Q1 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.